Scott Buzby

PHOENIX — Tovinontrine increased plasma cyclic guanosine monophosphate levels in patients with HF with reduced or preserved ejection fraction but

PHOENIX — Baroreflex activation therapy is commonly used off-label in a registry of real-world patients with heart failure who were well treated with guideline-directed medical therapy, a speaker reported.

The American Heart Association issued a science advisory statement outlining a framework for the investment of resources and funding to address the high prevalence of uncontrolled blood pressure in the U.S.

PHOENIX — A single up-front test may be able to detect early cardiac amyloidosis otherwise missed by other diagnostic modalities, a speaker reported at the Heart Failure Society of America Annual Scientific Meeting.

PHOENIX — Cardiac contractility modulation therapy continued to reduce heart failure hospitalizations and improved functional class and quality of life for many patients with heart failure with reduced ejection fraction, a speaker reported.The results of a mandated 1-year postmarket approval study of cardiac contractility modulation therapy (Impulse Dynamics) for patients with HFrEF were

Patients are increasingly turning to AI, social media and online searches for information about their health and medications, bringing both useful information and misinformation into the exam room.

PHOENIX — Approximately half of U.S. patients with heart failure also have elevated cardiovascular inflammation risk despite guideline-directed medical therapy, regardless of their ejection fraction, a speaker reported.

PHOENIX — Aficamten, a cardiac myosin inhibitor, was associated with improvements in symptom relief, diastolic function and parameters of exercise capacity beyond traditional measures such as peak oxygen uptake, speakers reported.The results of a study evaluating the global efficacy of aficamten (Myqorzo, Cytokinetics) on symptoms, exercise capacity, left atrium volume index, septal e

PHOENIX — Eplontersen monotherapy without baseline transthyretin stabilizers preserved the health status of patients with transthyretin amyloidosis with cardiomyopathy out to 140 weeks, a speaker reported.

PHOENIX — Cardiac microcurrent therapy, implanted surgically or subcutaneously, improved left ventricular ejection fraction and showed signals of improved exercise capacity in patients with heart failure, speakers reported.Positive results of the C-MIC II and C-MIC III trials of two cardiac microcurrent therapy devices (C-MIC, Berlin Heals Holding AG) designed to improve cardiac function